What question did this study set out to answer?

To examine the role of thioredoxin-1 in diffuse large B-cell lymphoma growth, survival, and chemoresistance, and to evaluate its viability as a therapeutic target.

March 23, 2012OncotargetOpen Access

Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

CLChangping LiUniversity of Louisville MTMichael A. ThompsonThe University of Melbourne ATArchito T. TamayoThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Preclinical study reveals that thioredoxin-1 drives tumor survival and chemoresistance in diffuse large B-cell lymphoma, indicating its potential as a therapeutic target to overcome drug resistance.

Key Points

To examine the role of thioredoxin-1 in diffuse large B-cell lymphoma growth, survival, and chemoresistance, and to evaluate its viability as a therapeutic target.
Measured baseline thioredoxin-1 (Trx-1) expression in DLBCL cell lines, primary patient samples, and normal B cells, analyzing correlation with patient survival.
Suppressed Trx-1 activity in DLBCL cells in vitro using small interfering RNA (siRNA) and the small-molecule inhibitor PX-12.
Assessed changes in cell proliferation, colony-forming capacity (clonogenicity), and sensitivity to doxorubicin following Trx-1 blockade.
Most DLBCL cell lines and primary patient cells demonstrated elevated basal Trx-1 levels relative to normal B cells, and high expression correlated with decreased overall survival.
Targeting Trx-1 via genetic knockdown or PX-12 significantly suppressed DLBCL cell growth and clonogenic potential in vitro.
Inhibition of Trx-1 restored cellular sensitivity to doxorubicin-mediated growth suppression, reversing chemoresistance.

Cite This Study

Li et al. (2012) studied this question.

synapsesocial.com/papers/6aab3765c2d7e755d7bfbea4 https://doi.org/10.18632/oncotarget.463

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals that thioredoxin-1 drives tumor survival and chemoresistance in diffuse large B-cell lymphoma, indicating its potential as a therapeutic target to overcome drug resistance.

Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider